Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease

Tomohiro Handa, Shoko Matsui, Hajime Yoshifuji, Yuzo Kodama, Hiroshi Yamamoto, Seijiro Minamoto, Yuko Waseda, Yasuharu Sato, Keishi Kubo, Tsuneyo Mimori, Tsutomu Chiba, Toyohiro Hirai, Michiaki Mishima

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: Serum soluble interleukin-2 (IL-2) receptor (sIL-2R) might reflect disease activity in immunoglobulin G4-related disease (IgG4-RD). We aimed to elucidate the clinical significance of blood markers, including sIL-2R, in patients with IgG4-RD. Methods: We enrolled 59 patients with IgG4-RD and investigated the association between blood markers (white blood cells, C-reactive protein, sIL-2R, IgG, IgG4, IgE, total hemolytic complement), and clinical indices. Results: At baseline, serum sIL-2R (Rs = 0.532, p < .001) and IgG4 (Rs = 0.545, p < .001) levels showed significant correlation to the number of organs involved. During follow-up period (median, 70 months; range, 7–195 months), 40 patients were treated with corticosteroids. Receiver operating characteristic (ROC) analysis showed that baseline sIL-2R levels most accurately predicted patients requiring glucocorticoid treatment (area under the ROC curve, 0.807). Among the 46 patients who improved, sIL-2R and IgG4 levels decreased in 42 and 41 patients, respectively. Among them, serum sIL-2R levels decreased to a normal range in 42 patients (91%), whereas IgG4 levels normalized in 19 (41%). Conclusion: The serum sIL-2R level is a potential biomarker for IgG4-RD that may reflect the number of involved organs and may predict patients requiring glucocorticoid treatment.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalModern Rheumatology
DOIs
Publication statusAccepted/In press - Jan 5 2018

Fingerprint

Interleukin-2 Receptors
Immunoglobulins
Interleukin-2
Biomarkers
Serum
Immunoglobulin G
ROC Curve
Glucocorticoids
Complement Hemolytic Activity Assay
C-Reactive Protein
Immunoglobulin E
Adrenal Cortex Hormones
Reference Values
Leukocytes
Therapeutics

Keywords

  • Biomarker
  • IgG4-related disease
  • soluble IL-2 receptor

ASJC Scopus subject areas

  • Rheumatology

Cite this

Handa, T., Matsui, S., Yoshifuji, H., Kodama, Y., Yamamoto, H., Minamoto, S., ... Mishima, M. (Accepted/In press). Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease. Modern Rheumatology, 1-7. https://doi.org/10.1080/14397595.2017.1416739

Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease. / Handa, Tomohiro; Matsui, Shoko; Yoshifuji, Hajime; Kodama, Yuzo; Yamamoto, Hiroshi; Minamoto, Seijiro; Waseda, Yuko; Sato, Yasuharu; Kubo, Keishi; Mimori, Tsuneyo; Chiba, Tsutomu; Hirai, Toyohiro; Mishima, Michiaki.

In: Modern Rheumatology, 05.01.2018, p. 1-7.

Research output: Contribution to journalArticle

Handa, T, Matsui, S, Yoshifuji, H, Kodama, Y, Yamamoto, H, Minamoto, S, Waseda, Y, Sato, Y, Kubo, K, Mimori, T, Chiba, T, Hirai, T & Mishima, M 2018, 'Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease', Modern Rheumatology, pp. 1-7. https://doi.org/10.1080/14397595.2017.1416739
Handa, Tomohiro ; Matsui, Shoko ; Yoshifuji, Hajime ; Kodama, Yuzo ; Yamamoto, Hiroshi ; Minamoto, Seijiro ; Waseda, Yuko ; Sato, Yasuharu ; Kubo, Keishi ; Mimori, Tsuneyo ; Chiba, Tsutomu ; Hirai, Toyohiro ; Mishima, Michiaki. / Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease. In: Modern Rheumatology. 2018 ; pp. 1-7.
@article{2e702188ed5d43c3a53b32deed67965a,
title = "Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease",
abstract = "Objectives: Serum soluble interleukin-2 (IL-2) receptor (sIL-2R) might reflect disease activity in immunoglobulin G4-related disease (IgG4-RD). We aimed to elucidate the clinical significance of blood markers, including sIL-2R, in patients with IgG4-RD. Methods: We enrolled 59 patients with IgG4-RD and investigated the association between blood markers (white blood cells, C-reactive protein, sIL-2R, IgG, IgG4, IgE, total hemolytic complement), and clinical indices. Results: At baseline, serum sIL-2R (Rs = 0.532, p < .001) and IgG4 (Rs = 0.545, p < .001) levels showed significant correlation to the number of organs involved. During follow-up period (median, 70 months; range, 7–195 months), 40 patients were treated with corticosteroids. Receiver operating characteristic (ROC) analysis showed that baseline sIL-2R levels most accurately predicted patients requiring glucocorticoid treatment (area under the ROC curve, 0.807). Among the 46 patients who improved, sIL-2R and IgG4 levels decreased in 42 and 41 patients, respectively. Among them, serum sIL-2R levels decreased to a normal range in 42 patients (91{\%}), whereas IgG4 levels normalized in 19 (41{\%}). Conclusion: The serum sIL-2R level is a potential biomarker for IgG4-RD that may reflect the number of involved organs and may predict patients requiring glucocorticoid treatment.",
keywords = "Biomarker, IgG4-related disease, soluble IL-2 receptor",
author = "Tomohiro Handa and Shoko Matsui and Hajime Yoshifuji and Yuzo Kodama and Hiroshi Yamamoto and Seijiro Minamoto and Yuko Waseda and Yasuharu Sato and Keishi Kubo and Tsuneyo Mimori and Tsutomu Chiba and Toyohiro Hirai and Michiaki Mishima",
year = "2018",
month = "1",
day = "5",
doi = "10.1080/14397595.2017.1416739",
language = "English",
pages = "1--7",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease

AU - Handa, Tomohiro

AU - Matsui, Shoko

AU - Yoshifuji, Hajime

AU - Kodama, Yuzo

AU - Yamamoto, Hiroshi

AU - Minamoto, Seijiro

AU - Waseda, Yuko

AU - Sato, Yasuharu

AU - Kubo, Keishi

AU - Mimori, Tsuneyo

AU - Chiba, Tsutomu

AU - Hirai, Toyohiro

AU - Mishima, Michiaki

PY - 2018/1/5

Y1 - 2018/1/5

N2 - Objectives: Serum soluble interleukin-2 (IL-2) receptor (sIL-2R) might reflect disease activity in immunoglobulin G4-related disease (IgG4-RD). We aimed to elucidate the clinical significance of blood markers, including sIL-2R, in patients with IgG4-RD. Methods: We enrolled 59 patients with IgG4-RD and investigated the association between blood markers (white blood cells, C-reactive protein, sIL-2R, IgG, IgG4, IgE, total hemolytic complement), and clinical indices. Results: At baseline, serum sIL-2R (Rs = 0.532, p < .001) and IgG4 (Rs = 0.545, p < .001) levels showed significant correlation to the number of organs involved. During follow-up period (median, 70 months; range, 7–195 months), 40 patients were treated with corticosteroids. Receiver operating characteristic (ROC) analysis showed that baseline sIL-2R levels most accurately predicted patients requiring glucocorticoid treatment (area under the ROC curve, 0.807). Among the 46 patients who improved, sIL-2R and IgG4 levels decreased in 42 and 41 patients, respectively. Among them, serum sIL-2R levels decreased to a normal range in 42 patients (91%), whereas IgG4 levels normalized in 19 (41%). Conclusion: The serum sIL-2R level is a potential biomarker for IgG4-RD that may reflect the number of involved organs and may predict patients requiring glucocorticoid treatment.

AB - Objectives: Serum soluble interleukin-2 (IL-2) receptor (sIL-2R) might reflect disease activity in immunoglobulin G4-related disease (IgG4-RD). We aimed to elucidate the clinical significance of blood markers, including sIL-2R, in patients with IgG4-RD. Methods: We enrolled 59 patients with IgG4-RD and investigated the association between blood markers (white blood cells, C-reactive protein, sIL-2R, IgG, IgG4, IgE, total hemolytic complement), and clinical indices. Results: At baseline, serum sIL-2R (Rs = 0.532, p < .001) and IgG4 (Rs = 0.545, p < .001) levels showed significant correlation to the number of organs involved. During follow-up period (median, 70 months; range, 7–195 months), 40 patients were treated with corticosteroids. Receiver operating characteristic (ROC) analysis showed that baseline sIL-2R levels most accurately predicted patients requiring glucocorticoid treatment (area under the ROC curve, 0.807). Among the 46 patients who improved, sIL-2R and IgG4 levels decreased in 42 and 41 patients, respectively. Among them, serum sIL-2R levels decreased to a normal range in 42 patients (91%), whereas IgG4 levels normalized in 19 (41%). Conclusion: The serum sIL-2R level is a potential biomarker for IgG4-RD that may reflect the number of involved organs and may predict patients requiring glucocorticoid treatment.

KW - Biomarker

KW - IgG4-related disease

KW - soluble IL-2 receptor

UR - http://www.scopus.com/inward/record.url?scp=85041126419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041126419&partnerID=8YFLogxK

U2 - 10.1080/14397595.2017.1416739

DO - 10.1080/14397595.2017.1416739

M3 - Article

C2 - 29251035

AN - SCOPUS:85041126419

SP - 1

EP - 7

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

ER -